Here is the information on the FDA Clinical Trial for pain and MS.

Duloxetine for Multiple Sclerosis Pain
This study is currently recruiting participants.
Verified by Eli Lilly and Company, March 2010

Keywords provided by Eli Lilly and Company:
Central Neuropathic Pain
Multiple Sclerosis


Purpose

This study is designed to primarily assess the efficacy and safety of duloxetine 60-120 mg once daily (QD)compared with placebo on the reduction of pain severity in patients with central neuropathic pain due to Multiple Sclerosis.

Detailed Description:

Study is a multicenter, randomized, double-blind, parallel, placebo-controlled, 20-week trial with 4 study periods. Patients who screen successfully (Study Period I) will be randomized in a 1:1 fashion to duloxetine 60 mg QD or placebo.

Starting with Study Period II, patients will be treated in a double-blind manner for 6 weeks. Patients who complete the 6-week, double-blind period will have the opportunity to participate in a 12-week, open-label, flexible-dose portion of the study (Study Period III).

Study Period IV is a taper phase designed to reduce the occurrence of discontinuation adverse events. Patients may enter Study Period IV at any time after Visit 3.

Legs, **There are 32 locations but you can ask your Neuro for other participating locations.**

For more information see FDA Clinical Trials below

http://clinicaltrials.gov/ct2/show/s...ow_locs=Y#locn


.